Yoshikatsu Kanai

Summary

Publications

  1. Kandasamy P, Gyimesi G, Kanai Y, Hediger M. Amino acid transporters revisited: New views in health and disease. Trends Biochem Sci. 2018;: pubmed publisher
  2. Nagamori S, Wiriyasermkul P, Okuda S, Kojima N, Hari Y, Kiyonaka S, et al. Structure-activity relations of leucine derivatives reveal critical moieties for cellular uptake and activation of mTORC1-mediated signaling. Amino Acids. 2016;48:1045-58 pubmed publisher
    ..Because LAT1-mTOR axis is involved in the regulation of cell growth and cancer progression, the results from this study may provide a new insight into therapeutics targeting both LAT1 and leucine sensor. ..
  3. Wei L, Tominaga H, Ohgaki R, Wiriyasermkul P, Hagiwara K, Okuda S, et al. Transport of 3-fluoro-L-α-methyl-tyrosine (FAMT) by organic ion transporters explains renal background in [(18)F]FAMT positron emission tomography. J Pharmacol Sci. 2016;130:101-9 pubmed publisher
    ..The results from this study would provide clues to the treatments to reduce renal background and enhance tumor uptake as well as to designing PET tracers with less renal accumulation. ..
  4. Ohgaki R, Wei L, Yamada K, Hara T, Kuriyama C, Okuda S, et al. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2. J Pharmacol Exp Ther. 2016;358:94-102 pubmed publisher
    ..After binding to SGLT2, canagliflozin may be reabsorbed by SGLT2, which leads to the low urinary excretion and prolonged drug action of canagliflozin. ..
  5. Gaccioli F, Aye I, Roos S, Lager S, Ramirez V, Kanai Y, et al. Expression and functional characterisation of System L amino acid transporters in the human term placenta. Reprod Biol Endocrinol. 2015;13:57 pubmed publisher
    ..In contrast to placental System A and beta amino acid transporters, MVM System L activity is unaffected by maternal overweight/obesity. ..
  6. Nagamori S, Wiriyasermkul P, Guarch M, Okuyama H, Nakagomi S, Tadagaki K, et al. Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT/SLC3A1. Proc Natl Acad Sci U S A. 2016;113:775-80 pubmed publisher
    ..Taken all together, AGT1 is the long-postulated second cystine transporter in the S3 segment of proximal tubules and a possible candidate to be involved in isolated cystinuria. ..
  7. Kongpracha P, Nagamori S, Wiriyasermkul P, Tanaka Y, Kaneda K, Okuda S, et al. Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 (LAT1). J Pharmacol Sci. 2017;133:96-102 pubmed publisher
    ..This study provides an additional insight into the structure-activity relationship of LAT1 ligands, which could lead to designing desirable LAT1 inhibitors. ..
  8. Ohgaki R, Ohmori T, Hara S, Nakagomi S, Kanai Azuma M, Kaneda Nakashima K, et al. Essential Roles of L-Type Amino Acid Transporter 1 in Syncytiotrophoblast Development by Presenting Fusogenic 4F2hc. Mol Cell Biol. 2017;37: pubmed publisher
  9. Ohgaki R, Teramura Y, Hayashi D, Quan L, Okuda S, Nagamori S, et al. Ratiometric fluorescence imaging of cell surface pH by poly(ethylene glycol)-phospholipid conjugated with fluorescein isothiocyanate. Sci Rep. 2017;7:17484 pubmed publisher
    ..This study further indicates that various probes useful for the investigation of juxtamembrane environments could also be developed by using PEG-lipid as the core structure for bio-membrane anchoring. ..

More Information

Publications10

  1. Kaira K, Sunose Y, Ohshima Y, Ishioka N, Arakawa K, Ogawa T, et al. Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. BMC Cancer. 2013;13:482 pubmed publisher
    ..High expression of LAT1 is a promising pathological marker to predict the outcome in patients with biliary tract adenocarcinoma. Inhibition of LAT1 may be an effective targeted therapy for this distressing disease. ..